- Home
- IOVA vs WDAY Comparison
IOVA vs WDAY Comparison
Compare IOVA & WDAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- WDAY
- Stock Information
- Founded
- IOVA 2007
- WDAY 2005
- Country
- IOVA United States
- WDAY United States
- Employees
- IOVA N/A
- WDAY N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- WDAY EDP Services
- Sector
- IOVA Health Care
- WDAY Technology
- Exchange
- IOVA Nasdaq
- WDAY Nasdaq
- Market Cap
- IOVA 1.0B
- WDAY N/A
- IPO Year
- IOVA N/A
- WDAY 2012
- Fundamental
- Price
- IOVA $1.73
- WDAY $259.03
- Analyst Decision
- IOVA Strong Buy
- WDAY Buy
- Analyst Count
- IOVA 9
- WDAY 30
- Target Price
- IOVA $18.22
- WDAY $299.48
- AVG Volume (30 Days)
- IOVA 9.3M
- WDAY 1.6M
- Earning Date
- IOVA 05-08-2025
- WDAY 05-22-2025
- Dividend Yield
- IOVA N/A
- WDAY N/A
- EPS Growth
- IOVA N/A
- WDAY N/A
- EPS
- IOVA N/A
- WDAY 1.95
- Revenue
- IOVA $164,070,000.00
- WDAY $8,446,000,000.00
- Revenue This Year
- IOVA $182.20
- WDAY $14.78
- Revenue Next Year
- IOVA $62.10
- WDAY $13.48
- P/E Ratio
- IOVA N/A
- WDAY $132.03
- Revenue Growth
- IOVA 13698.99
- WDAY 16.35
- 52 Week Low
- IOVA $2.70
- WDAY $199.81
- 52 Week High
- IOVA $13.60
- WDAY $294.00
- Technical
- Relative Strength Index (RSI)
- IOVA 24.56
- WDAY 67.01
- Support Level
- IOVA $3.02
- WDAY $245.77
- Resistance Level
- IOVA $3.31
- WDAY $260.34
- Average True Range (ATR)
- IOVA 0.24
- WDAY 5.61
- MACD
- IOVA -0.08
- WDAY 3.10
- Stochastic Oscillator
- IOVA 6.00
- WDAY 96.06
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.